Lipitor v. Pravachol Studies Raise Questions On Utility Of OTC-Dose Statins
This article was originally published in The Tan Sheet
Executive Summary
Two recently published clinical trials involving statins that report a clear and substantial benefit from intensive LDL-cholesterol lowering versus moderate reduction may dampen prospects for switching the drugs OTC in the U.S
You may also be interested in...
Kos Statin/Niacin Fixed Dose Combo To Be Supported By NHLBI-Funded Trial
The National Heart, Lung & Blood Institute will provide more than $20 mil. in funding for a clinical study comparing a simvastatin/niacin combination therapy to simvastatin alone for prevention of cardiovascular events
Simvastatin Myopathy Rate Spells Trouble For High Doses In “A to Z” Trial
An increased rate of myopathy in study participants taking an 80 mg dose of Merck's Zocor (simvastatin) suggests that high doses of the drug "should be used with caution," according to an editorial slated for publication in the Sept. 15 Journal of the American Medical Association
Round Two: Mevacor Switch Will Need To Quiet Undertreatment Questions
One of J&J/Merck's key challenges in pursuing an OTC switch for Mevacor (lovastatin) will be convincing FDA that labeling can alleviate the risk of undertreating high cholesterol